Sacchetti Federico, Aston Will, Pollock Rob, Gikas Panos, Cuomo Pierluigi, Gerrand Craig
Divisione di Ortopedia Oncologica e Ricostruttiva, Careggi University Hospital (Azienda Ospedaliero Universitaria Careggi), Florence, Italy.
Royal National Orthopaedic Hospital NHS Trust, London, UK.
Bone Jt Open. 2022 Sep;3(9):733-740. doi: 10.1302/2633-1462.39.BJO-2022-0069.R1.
The proximal tibia (PT) is the anatomical site most frequently affected by primary bone tumours after the distal femur. Reconstruction of the PT remains challenging because of the poor soft-tissue cover and the need to reconstruct the extensor mechanism. Reconstructive techniques include implantation of massive endoprosthesis (megaprosthesis), osteoarticular allografts (OAs), or allograft-prosthesis composites (APCs).
This was a retrospective analysis of clinical data relating to patients who underwent proximal tibial arthroplasty in our regional bone tumour centre from 2010 to 2018.
A total of 76 patients fulfilled the inclusion criteria and were included in the study. Mean age at surgery was 43.2 years (12 to 86 (SD 21)). The mean follow-up period was 60.1 months (5.4 to 353). In total 21 failures were identified, giving an overall failure rate of 27.6%. Prosthesis survival at five years was 75.5%, and at ten years was 59%. At last follow-up, mean knee flexion was 89.8° (SD 36°) with a mean extensor lag of 18.1° (SD 24°). In univariate analysis, factors associated with better survival of the prosthesis were a malignant or metastatic cancer diagnosis (versus benign), with a five- and ten-year survival of 78.9% and 65.7% versus 37.5% (p = 0.045), while in-hospital length of stay longer than nine days was also associated with better prognosis with five- and ten-year survival rates at 84% and 84% versus 60% and 16% (p < 0.001). In multivariate analysis, only in-hospital length of stay was associated with longer survival (hazard ratio (HR) 0.23, 95% confidence interval (CI) 0.08 to 0.66).
We have shown that proximal tibial arthroplasty with endoprosthesis is a safe and reliable method for reconstruction in patients treated for orthopaedic oncological conditions. Either modular or custom implants in this series performed well.Cite this article: 2022;3(9):733-740.
胫骨近端(PT)是仅次于股骨远端,最常受原发性骨肿瘤影响的解剖部位。由于软组织覆盖较差且需要重建伸膝机制,PT的重建仍然具有挑战性。重建技术包括植入大型内置假体(巨型假体)、骨关节异体移植(OA)或异体移植-假体复合物(APC)。
这是一项对2010年至2018年在我们地区骨肿瘤中心接受胫骨近端关节置换术患者的临床数据进行的回顾性分析。
共有76例患者符合纳入标准并被纳入研究。手术时的平均年龄为43.2岁(12至86岁(标准差21))。平均随访期为60.1个月(5.4至353个月)。共发现21例失败病例,总体失败率为27.6%。假体5年生存率为75.5%,10年生存率为59%。在最后一次随访时,平均膝关节屈曲度为89.8°(标准差36°),平均伸膝滞后为18.1°(标准差24°)。在单因素分析中,与假体更好生存率相关的因素是恶性或转移性癌症诊断(相对于良性),5年和10年生存率分别为78.9%和65.7%,而良性为37.5%(p = 0.045),同时住院时间超过9天也与更好的预后相关,5年和10年生存率分别为84%和84%,而良性为60%和16%(p < 0.001)。在多因素分析中,只有住院时间与更长的生存率相关(风险比(HR)0.23,95%置信区间(CI)0.08至0.66)。
我们已经表明,使用内置假体进行胫骨近端关节置换术是治疗骨科肿瘤疾病患者进行重建的一种安全可靠的方法。本系列中的模块化或定制植入物表现良好。引用本文:2022;3(9):733 - 740。